11 rue de l’académie
67000 Strasbourg
140 rue du Chevaleret,
75013 Paris, France
BRAINTALE, whose head office is 11 rue de l’Académie 67000 – STRASBOURG, is registered in the Trade and Companies Register under number 840 995 138 RCS STRASBOURG
Last update : 09/19/2022
Virginie MIATH is an Investment Director at Capital Grand Est, holds triple Master degrees from the University Paris-Sud and Groupe INSEEC in Paris, in fields of Genetics, Innovation Economics, and Corporate Finance. She has more than 15 years of in-depth professional experience in various fields around technology transfer, business and finance, including start-up development as well as management of research and investment projects.
Founder and CEO of LallianSe, Julie Rachline is a serial entrepreneur with nearly 20 years of experience in life sciences and venture capital with start-ups, scale-ups, investors and corporations. LallianSe, pioneer and initiator of the life sciences integrator concept, was created in 2015 to transform innovations into economic successes through the co-construction and execution of compelling equity stories.
Julie is CEO of Braintale, the flagship initiative co-founded by LallianSe, which deciphers white matter to enable better brain care. Board member of Braintale, she is also independent board member with EverZom and presides the nonprofit Association LallianSe for healthcare innovation and is general secretary of Paris Region Greater Hospitals spin outs nonprofit organization. She is also member of the Mission committee of Relyens.
Thierry Mignot joined BrainTale in 2022 as chief financial officer.
After 20 years’ corporate CFO experience in outsourced banking services, textile industry, home healthcare services and diabetes research, Thierry launched an outsourced timeshare CFO service in 2014 and support several young innovative companies in the Strasbourg healthcare ecosystem by providing his expertise in administrative, financial and HR management.
Florence Kocher joined BrainTale in 2023.
With almost a decade of experience in Sales and Marketing strategies to bring innovative medical devices on the market, she is in charge of BrainTale commercial operations. Before joining BrainTale she worked at Urgo Medical in France, in Germany and in global positions. She finally acted as global Marketing and Professional Relations Director, supervising global marketing operations and product launches.
Sébastien Couvet has been head of e-health startup portfolio management and portfolio manager in MACSF’s finance department since 2022. He joined the group in 2019 after initial experience at Caisse des Dépôts et Consignations.
He graduated in financial engineering from the University of Cergy-Pontoise in 2018.
Eric Garnier has 35 years of experience in healthcare and medical devices management, acquired in multinational industries (BMS, Danaher) including more than a decade of expatriation in London, Singapore and Boston. Today he is an advisor and belongs to the Angels Santé’s bureau.
Dr Nitza Thomasson is the co-founder of Gensight Biologics (Gene therapy for ophthalmologic diseases) and BrainEver (Advanced medicinal products to treat neurodegenerative diseases). After a post doc at Northwestern & Rush University (Chicago, USA), she joined the pharma industry to develop medicines for neurologic and psychiatric disorders at Servier. Then she moved to the biotech world, joining Fovea Pharma in 2009, that became Ophthalmology Division of Sanofi. She contributed to the start of Tissium (2014 – Head of Development), while co-founding GenSight Biologics (2013 – Preclinical and CMC Officer), then BrainEver (2015 – Chief Operating Officer). In 2018, Nitza founded NtzConsulting.
Nitza is also Venture Partner at OmnesCapital. She is board member to support innovation and growth in the healthcare company portfolio.
Professor Spyros Artavanis-Tsakonas is Professor Emeritus in the Department of Cell Biology at Harvard Medical School. In 1999, he was elected Professor at the Collège de France, holding the Chair of Biology and Genetics of Development until 2012 when he became Professeur honoraire. He is the Founding Director of the Department of Genetics and Developmental Biology at Institut Curie, Paris. From 2012 to March 2017, he served as Chief Scientific Officer and Executive Vice President at Biogen Inc.
He is a fellow of the American Academy of Arts and Sciences, an associate member of EMBO, and a corresponding member of the Academy of Athens and a member of the Cambridge Philosophical Society, co-founder and president of Fondation Sante, a charitable organization supporting Biomedical research in Greece, and co-founder of Exelixis, Cellzome and Anadys.
Jean-Baptiste joined BrainTale in 2021. With more than 15 years of experience in medical imaging software, he is in charge of products development . Jean-Baptiste co-founded Qynapse and served as the imaging R&D leader, in charge of the development, certification and roll-out of Qynapse software for image analysis and processing. He also was software engineer for the neuroimaging platform CATI and worked at Dosisoft. Jean-Baptiste holds a master’s in artificial intelligence from Sorbonne University, Paris.
Dorothée has joined BrainTale in 2019 as director of clinical affairs and she is now chief of regulatory and clinical affairs officer. Dorothée holds of a MSc in pharma-biotech from the Faculty of Pharmacy of Reims. With more than 15 years of experience with knowledge of clinical operations, clinical evaluation, regulatory environment, market access and business development. She served in various positions for 15 years in diverse organisations from medical devices companies to CROs, operating both in Europe and in the US.
Co-founder, Vincent has been BrainTale’spresident and Chief Scientific Officer since 2018. He has both engineer degree from Grenoble INP and PhD in Medical Physics in 2007 from Paris XI University. Thorough his research, at Sorbonne Universiy and Brain and Spine Institute (ICM, Paris) he authored more than 70 articles (h-index = 29) on advanced methods for neuroimaging data analysis in neuroscience and in various clinical applications as traumatic brain injuries, stroke or neurodegenerative diseases.
